SCHEMBL1896676

SCHEMBL1896676

COCc1[c]c2ccccc2cc1

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.32
CYP2A6 P11509 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2498030 0.81 TSHR (0.33) CYP1A2CYP2A6
SCHEMBL2500666 0.81
SCHEMBL66086 0.78 CYP1A2 (0.39) CYP1A2CYP2A6
SCHEMBL11863358 0.77 CYP2A6 (0.32) CYP1A2CYP2A6
SCHEMBL258245 0.74 KDM4E (0.33) CYP1A2CYP2A6
SCHEMBL6897074 0.74 LOXL2 (0.37) CYP2A6
SCHEMBL6674217 0.74 TRPA1 (0.32)
SCHEMBL4271458 0.74 TSHR (0.32) CYP2A6
SCHEMBL9466571 0.74 TRPA1 (0.32)
SCHEMBL3525598 0.74 L3MBTL1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2493571-B1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-07-23 EP claimed
US-8633322-B2 Alkynyl derivatives useful as DPP-1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-01-21 US claimed
EP-2493571-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2012-09-05 EP claimed
WO-2011059731-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-05-19 WO claimed
US-20110105562-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2011-05-05 US claimed
EP-2493571-B1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-07-23 EP disclosed
US-8633322-B2 Alkynyl derivatives useful as DPP-1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-01-21 US disclosed
US-8497334-B2 Conjugated diene polymer, conjugated diene polymer composition, and method for producing conjugated diene polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-07-30 US disclosed
EP-2493571-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2012-09-05 EP disclosed
US-8071598-B2 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-12-06 US disclosed
US-20110245407-A1 CONJUGATED DIENE POLYMER, CONJUGATED DIENE POLYMER COMPOSITION, AND METHOD FOR PRODUCING CONJUGATED DIENE POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-10-06 US disclosed
CN-102206305-A Conjugated diene polymer,conjugated diene polymei composition, and method for producing conjugated diene polymer SUMITOMO CO LTD 2011-10-05 CN disclosed
US-20110105562-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2011-05-05 US disclosed
US-20100160333-A1 NOVEL 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS ANIONA APS (DK) 2010-06-24 US disclosed
US-7700596-B2 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2010-04-20 US disclosed
US-20090036456-A1 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS ANIONA APS (DK) 2009-02-05 US disclosed
EP-1984365-A1 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-10-29 EP disclosed
WO-2007090886-A1 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-08-16 WO disclosed
EP-0833822-A1 4-PHENYLAMINOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES SANOFI (FR) 1998-04-08 EP disclosed
WO-1997000868-A1 4-PHENYLAMINOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES SANOFI (FR) 1997-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160333-A1 NOVEL 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC6A3, SLC6A2 CYP1A2 195/4885CYP2A6 429/4885
US-20110105562-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS DPP4, DPP3, DPP7 CYP1A2 1875/4885CYP2A6 1200/4885
US-20090036456-A1 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 CYP1A2 241/4885CYP2A6 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.